Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas

Cancer Research

Volumn 71, Issue 7, 2011, Pages 2428-2432

  Iyer, Arun K ^a   Lan, Xiaoli ^a   Zhu, Xiaodong ^b   Su, Yang ^a,b   Feng, Jinjin ^a   Zhang, Xiaoju ^b   Gao, Dongwei ^a   Seo, Youngho ^a,c   VanBrocklin, Henry F ^a,c   Broaddus, V Courtney ^a,c   Liu, Bin ^b,c   He, Jiang ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EPITHELIOID MESOTHELIOMA; INTERNALIZATION; MALE; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SARCOMATOID MESOTHELIOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL;

ANIMALS; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOTOXINS; ISOTOPE LABELING; MALE; MESOTHELIOMA; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOMA; SINGLE-CHAIN ANTIBODIES; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79953309470     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3484     Document Type: Article

References (20)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603. (Pubitemid 41434638)
2. Tsiouris A, Walesby R. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 2007;4:344-52. (Pubitemid 46864308)
3. Kindler H. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004;45:125-7.
4. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A 2005;102:17757-62. (Pubitemid 41803570)
5. Garnett MC. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 2001;53:171-216. (Pubitemid 33135563)
6. An F, Drummond DC, Wilson S, Kirpotin DB, Nishimura SL, Broaddus VC, et al. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther 2008;7:569.
7. Zeng L, Fleury-Feith J, Monnet I, Boutin C, Bignon J, Jaurand MC. Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. Hum Pathol 1994;25:227-34. (Pubitemid 24116236)
8. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42. (Pubitemid 38812466)
9. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006;19:34-48. (Pubitemid 43250977)
10. Bidlingmaier S, He J, Wang Y, An F, Feng J, Barbone D, et al. Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of Mesothelioma. Cancer Res 2009;69:1570.
11. Liu B, Conrad F, Cooperberg M, Kirpotin D, Marks J. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res 2004;64:704.
12. Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, et al. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 2007;6:2737.
13. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002;1591:109-18. (Pubitemid 35232074)
14. Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, Stichelberger A, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc (I)-carbonyl complex. Nat Biotechnol 1999;17:897-901.
15. Ruan W, Sassoon A, An F, Simko J, Liu B. Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics 2006;5:2364.
16. He J, Wang Y, Feng J, Zhu X, Lan X, Iyer AK, et al. Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med 2010;51:427-32.
17. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn Jr P. Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89. (Pubitemid 14091996)
18. Olafsen T, Kenanova V, Wu A. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 2006;1:2048-60. (Pubitemid 46773329)
19. Tsuji AB, Sogawa C, Sugyo A, Sudo H, Toyohara J, Koizumi M, et al. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nucl Med Biol 2009;36:379-88.
20. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998;114:713-22. (Pubitemid 28433730)